The findings, published in BMC Biology, connect population genetics with clinical infectious-disease research. The investigators examined the evolutionary history of IL-4, TLR2, CCL2 and SLC11A1, genes involved in regulating inflammation and the detection or control of invading pathogens. They then compared genetic variation in these genes with clinical outcomes among nearly 4,000 people in Italy who had tested positive for SARS-CoV-2 through the Italian GEN-COVID study.

The evolutionary analysis used genetic data from more than 2,000 individuals representing African, European and Asian populations. The researchers searched for patterns consistent with natural selection, including differences in allele frequencies between populations and other signatures indicating that particular genetic variants had been favored or removed over time. All four genes showed evidence of evolutionary change, although the patterns differed across regions. That variation suggests that infectious diseases and other environmental pressures have shaped immune responses along distinct population histories.

Natural selection can act on immune genes in complex ways. A variant that improves resistance to one pathogen may increase the risk of excessive inflammation or another disease under different conditions. Immune genes are therefore often subject to balancing pressures rather than a single, universally beneficial genetic solution. The study’s results indicate that the versions of these genes common today may reflect long-term compromises between pathogen defense, inflammatory damage and changing environments.

The researchers also compared modern human sequences with genetic material from Neanderthals and Denisovans, extinct relatives of modern humans. Some shared variants may have been inherited from a common ancestor, while others could reflect interbreeding between ancient modern humans and these archaic populations. Such exchanges introduced genetic material into ancestral human populations tens of thousands of years ago, potentially including immune-related variants that influenced how later generations responded to infectious organisms.

These evolutionary signatures were established long before SARS-CoV-2 appeared. The coronavirus did not create the ancient patterns detected in the four genes; instead, it encountered immune systems already shaped by earlier infectious threats. “SARS-CoV-2, the coronavirus that causes COVID-19, may be new, but the immune system it encountered isn’t,” said Michael Campbell, an associate professor of biological sciences at USC Dornsife and the study’s senior author. The distinction is important because it frames COVID-19 susceptibility as a possible consequence of pre-existing biological variation rather than a response that evolved during the pandemic.

The clinical analysis produced a more recent and specific finding involving TLR2, which encodes Toll-like receptor 2. TLR2 is part of the innate immune system, the body’s rapid first line of defense against infection. It recognizes molecular patterns associated with microbes and activates signaling pathways that stimulate inflammatory responses. Two rare TLR2 variants were identified in the Italian COVID-19 dataset. One occurred more frequently among patients who had previously received organ transplants, while the other was associated with more severe COVID-19.

The transplant-related observation is notable because organ-transplant recipients already face elevated risks from COVID-19. Immunosuppressive medications used to prevent rejection can weaken antiviral defenses, while the underlying medical conditions of recipients may further increase vulnerability. A rare alteration in TLR2 could potentially add another layer of risk by changing pathogen recognition or downstream inflammatory signaling. However, the study does not establish that either variant causes severe disease, and the observed associations may be influenced by sample size, population structure or other clinical factors.

The researchers emphasize that the TLR2 results require replication in larger and more genetically diverse groups. Rare variants are particularly difficult to evaluate because they occur infrequently, meaning that even a study involving thousands of participants may contain only a small number of carriers. Independent cohorts, functional laboratory experiments and mechanistic studies will be needed to determine whether the variants alter TLR2 expression, protein activity or immune signaling during SARS-CoV-2 infection. Broader sampling will also help clarify whether the associations apply beyond the Italian population.

By combining evolutionary genomics with patient data, the study illustrates how ancient genetic history can guide investigations of modern viral disease. Genes shaped by past pathogens may contain clues to why individuals respond differently to the same infection, while rare mutations can reveal additional vulnerabilities that are invisible when researchers focus only on common variation. The authors say that this approach could eventually identify biological pathways useful for predicting disease risk or developing new preventive and therapeutic strategies, although such applications remain a future possibility rather than an immediate clinical outcome.

Subject of Research: People

Article Title: The evolutionary landscape of host immunity genes involved in respiratory and other immune-related diseases, and the identification of TLR2 variation associated with severe COVID-19

News Publication Date: 29-May-2026

Web References: https://doi.org/10.1186/s12915-026-02623-6

References: BMC Biology, DOI: 10.1186/s12915-026-02623-6

Keywords: COVID-19, SARS-CoV-2, TLR2, immune genes, evolutionary genetics, natural selection, rare genetic variants, severe disease, organ transplantation, infectious diseases

The study involved an extensive analysis of cognitive and biological responses from a cohort of individuals with chronic HIV and HCV infections. Researchers employed advanced statistical modeling to correlate genotype variations with clinical outcomes. The results indicated that individuals with the CC genotype of the IFNL4 gene experienced a heightened state of immune exhaustion, which in turn leads to faster disease progression. This information adds to the growing body of literature surrounding the critical role of genetics in shaping individual health outcomes, particularly in chronic viral infections.

Terminal exhaustion is characterized by CD8+ T-cell depletion, which is a result of persistent viral load and chronic inflammation. The research findings shed light on the mechanisms at play in this reduced immune response. It becomes evident that individuals possessing the CC genotype exhibit lower levels of critical immune markers and more pronounced signs of senescence, indicating their immune cells are aging prematurely. This biological insight demonstrates the interplay between genetic predisposition and chronic disease trajectories, highlighting the need for personalized medicine approaches.

Moreover, the study suggests that the discovery of the IFNL4 genotype could lead to novel therapeutic strategies aimed at enhancing the immune response in genetically predisposed individuals. Therapies and interventions could be designed specifically for patients with the CC genotype to restore immune function and mitigate the effects of senescence. Such advancements underscore the potential for genetic testing in clinical practice, allowing for better-targeted therapies that could ultimately improve patient outcomes.

The implications for public health are considerable. With rising incidences of HIV and HCV globally, understanding the genetic underpinnings of these diseases can allow healthcare professionals to identify individuals at higher risk for severe outcomes based on their genetic profile. Policymakers can utilize this information when planning screening and intervention strategies, ensuring that resources are allocated effectively to those who need them most. Moreover, awareness campaigns aimed at educating high-risk populations about their genetic risks could empower individuals to seek timely testing and treatment options.

As more studies emerge in this field, the conversation regarding personalized medicine continues to expand. The approaches to treating chronic viral infections could become more tailored, with a shift toward acknowledging genetic variability among patients. Traditional methods that rely on a one-size-fits-all approach may become obsolete as healthcare transitions towards more nuanced and individualized care pathways based on genetic profiles.

In addition, this research opens the door for a broader exploration into how other genetic factors contribute to the progression of various chronic diseases. The focus on IFNL4 will likely spur additional studies into other genes and their roles in immunity and chronic disease processes. This expanding knowledge base will further fortify the connection between genetics, immunology, and clinical outcomes, creating a comprehensive understanding of disease mechanisms.

As researchers continue to unravel the intricate genetics associated with chronic viral infections, the potential for new biomarker discovery increases. Identifying additional biomarkers could transform how chronic infections are monitored and managed. By combining this genetic data with other clinical factors, healthcare providers may be able to develop more robust predictive models, improving prognosis and treatment timelines.

The study’s findings are particularly relevant given the increasing incidence rates of HIV and HCV across various populations. The relationship between genetic predisposition and disease outcomes is increasingly apparent, prompting a reevaluation of how these factors are integrated into clinical practice. As more emphasis is placed on genetics in medicine, future research will likely investigate the potential for lifestyle modifications and therapeutic interventions to mitigate risks associated with adverse genetic profiles.

Chronic viral infections pose a significant public health challenge worldwide. As such, the advancements revealed in this research highlight the importance of integrating genetic research into public health strategies. By understanding genetic predispositions, health organizations can develop tailored prevention tactics and treatment pathways, ultimately aiming to reduce the burden of disease in susceptible populations.

In summary, the research conducted by Arca-Lafuente et al. represents a significant stride in our understanding of viral infections and their genetic underpinnings. The CC genotype of IFNL4 emerges as a crucial player in the acceleration of immune exhaustion and senescence in chronic infections of HIV and HCV. The study not only emphasizes the relevance of genetic factors in disease progression but also encourages a shift towards personalized medicine, aiming for better-targeted therapies and improved healthcare outcomes in vulnerable populations.

The evolution of genetic research in chronic infections signals a paradigm shift within the medical community. As we glean insights from such studies, the pathway towards individualized treatment regimens becomes increasingly attainable, marking a new era in chronic disease management. The promise of personalized medicine underscores a critical transformation in how we approach healthcare, making it imperative for researchers and clinicians alike to continue to investigate the intricate relationship between genetics and disease.

This transformation is essential not only for current patients but also for future generations who will benefit from a more refined understanding of genetic influences on disease. Ultimately, the findings from this study pave the way for a healthcare system that prioritizes individualized care, informed by genetic insights, aiming to provide effective and equitable treatment solutions for all.

Subject of Research: Genetic predisposition to accelerated terminal exhaustion and senescence in HIV/HCV chronic infections.

Article Title: IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infection.

Article References: Arca-Lafuente, S., Lara-Aguilar, V., Llamas-Adán, M. et al. IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infection. J Transl Med 23, 1432 (2025). https://doi.org/10.1186/s12967-025-07070-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07070-5

Keywords: IFNL4 genotype, chronic infections, HIV, HCV, immune exhaustion, senescence, personalized medicine, public health, genetic research, chronic disease management.